Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

Breast Cancer Clinical Trial

Official title:

Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02312934
• Other study ID #: 141584
• Status: Completed
• Phase: Phase 2
• Start date: August 2015
• Est. completion date: May 2018

Study information

• Verified date: January 2020
• Source: Vanderbilt University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the use of a nicotine patch as a treatment for problems with attention, learning and memory in breast cancer patients who are 1-5 years post chemotherapy.

Description:

Studies have suggested that chemotherapy treatment for breast cancer may change the way the brain functions. As a result, patients who receive chemotherapy for breast cancer may experience problems with their attention, learning, and memory that they did not have before receiving chemotherapy. The investigators have found that nicotine treatment can help other types of patients with similar difficulties with attention, learning, and memory. Nicotine is a naturally occurring substance found in tobacco and is known to interact with nerve cells in the brain that are important for functions like learning and memory, and has been studied in a number of disorders. This study is designed to test whether nicotine treatment is helpful for learning and memory problems after chemotherapy for breast cancer.

This study will be a randomized, placebo-controlled pilot study to evaluate the effect of transdermal nicotine to 1) reduce subjective complaints and 2) enhance cognitive performance on laboratory measures of cognitive performance in breast cancer patients with persistent chemotherapy-related cognitive impairment (CRCI), a condition also known as "chemo brain." Participants will be randomized to either placebo or active compound (50/50) for the 6-week treatment portion of the study. Participants will be assessed before, during, and at the end of treatment. At the end of the 8-week study, participants will have the option to take part in the open-label portion of the study for an additional 6 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: May 2018
• Est. primary completion date: May 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

• All participants will:

1. Be between 35 and 80 years of age,

2. Have been diagnosed with noninvasive or invasive (Stage 1, 2, or 3A) breast cancer,

3. Have undergone treatment with systemic chemotherapy within the last 1-5 years,

4. Endorse persistent CRCI subjective complaints,

5. Be non-smokers (no nicotine use within the last 5 years),

6. Have no active cardiac, neurologic, or psychiatric illness, and

7. Fluent in and able to read English.

Exclusion Criteria:

• Participants will be excluded for:

1. Any active neurologic and/or psychiatric disease, history of significant head trauma followed by persistent neurologic deficits, or known structural brain abnormalities,

2. Current major depression or another major psychiatric disorder as described in DSM-5 (use of CNS active medications (e.g. antidepressants) will be permitted, provided dosing has been stable for at least 3 months),

3. Any history of alcohol or substance abuse or dependence within the past 2 years (DSM-5 criteria),

4. Any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including:

• History of myocardial infarction in the past year or unstable, severe cardiovascular disease including angina or CHF with symptoms at rest, or clinically significant abnormalities on the ECG

• Clinically significant and/or unstable pulmonary, gastrointestinal, hepatic, or renal disease

• Insulin-requiring diabetes or uncontrolled diabetes mellitus,

• Uncontrolled hypertension (systolic BP> 170 or diastolic BP> 100), 5. Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer, prior to screening, and 6. Use of any drugs with pro-cholinergic properties (e.g. donepezil).

Related Conditions & MeSH terms

• Breast Cancer
• Chemo Brain
• Chemo Fog
• Chemobrain
• Chemotherapy-related Cognitive Impairment
• Cognitive Dysfunction

Intervention

Drug:
• Transdermal nicotine
Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.

Other:
• Placebo Transdermal Patch
Matching transdermal placebo patches will be used. Participants will follow the same titration schedule as the transdermal nicotine arm.

Locations

Country	Name	City	State
United States	Center for Cognitive Medicine at Vanderbilt University	Nashville	Tennessee

Sponsors (1)

Lead Sponsor	Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) PCI Scale	The Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) scale will be used to monitor change in CRCI subjective complaints.; This instrument has been used to monitor change in CRCI subjective complaints in previous studies and demonstrates good internal consistency, test-retest reliability, and discriminant and convergent validity. Specifically, the PCI subscale was used as the primary outcome measure.; The FACT-Cog PCI consists of 20 items and has a minimum score of 0 and total possible score of 72. Higher scores indicate better cognitive functioning.; The PCI evaluates memory, concentration, mental acuity, verbal fluency, functional interference, and multitasking ability.; Visit 3 is the 3-week visit, Visit 4 is the 6-week visit, and Visit 5 is the 8-week visit.; Change scores were calculated as follow	Baseline to 8-Weeks
Secondary	Conners Continuous Performance Test	The secondary outcome measure was the computerized Conners Continuous Performance Test (CPT), which measures sustained attention and vigilance. Participants see a series of letters appearing one at a time on a computer screen and they press a button for every letter that appears on the screen, except for "X". Lower scores indicate better performance.; Scores on the CPT are calculated using the each participant's performance on the task (defined as reaction time (in ms) standard error/interstimulus interval). Change scores from baseline are then calculated. A decrease in CPT score = improvement.; *This is not a clinical measure. This is a research measure of reaction time variability and therefore there is no clinical interpretation and no defined score range.*	Baseline to 8 Weeks